Overall, Ki‐67, Cyclin D1, PHH3, and PCNA biomarkers can potentially improve pancreatic cancer clinical management by providing valuable information about disease progression and treatment response [9]. This evidence concerns the gene CCND1 and familial pancreatic carcinoma.